| تعداد نشریات | 285 |
| تعداد نشریات سازمان | 83 |
| تعداد شماره‌ها | 3,086 |
| تعداد مقالات | 34,442 |
| تعداد مشاهده مقاله | 48,918,885 |
| تعداد دریافت فایل اصل مقاله | 79,355,690 |
Safety evaluation of umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) in the treatment of patients with multiple sclerosis | ||
| Archives of Razi Institute | ||
| مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 15 مرداد 1404 اصل مقاله (493.66 K) | ||
| نوع مقاله: Original Articles | ||
| شناسه دیجیتال (DOI): 10.22092/ari.2025.368946.3583 | ||
| نویسندگان | ||
| Mohamad Mahdi Esmaeili Araghi1؛ Mehrdad Moosazadeh Moghaddam2؛ Hadi Esmaeili Gouvarchin Ghaleh3؛ Mehdi Raei4؛ Bahman Jalali Kondori5؛ Akbar Ghorbani Alvanegh6؛ Seyed Javad Hosseini Nejad Anbaran* 7 | ||
| 1Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. | ||
| 2Tissue Engineering and Regenerative Medicine Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. | ||
| 3Applied Virology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. | ||
| 4Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. | ||
| 5Department of Anatomical Sciences, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran. Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran | ||
| 6Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. | ||
| 7Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran | ||
| چکیده | ||
| Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to symptoms like fatigue, mobility issues, and cognitive decline. Available treatments include disease-modifying therapies (DMTs) and symptom management options. However, many patients experience limited effectiveness, side effects, or inadequate response, highlighting the need for innovative therapeutic approaches. Given the potential of mesenchymal stem cells (MSCs) to modulate immune responses and promote neuroprotection, this study aims to assess safety of UC-MSCs, paving the way for future therapeutic applications in MS management. In this study, five patients with MS were selected based on McDonald criteria and specific inclusion criteria, including age, EDSS score, and absence of certain medical conditions. Pre-injection assessments included ECG, MRI, and comprehensive blood and urine tests. Patients received UC-MSCs in normal saline over 20 minutes, followed by hydrocortisone. Post-injection, patients were monitored in the hospital for 24-48 hours, with vital signs checked every 1 to 3 hours. Blood and urine tests were repeated 24 hours after injection and again one month later to evaluate safety and monitor for adverse effects. Our result showed that the differences in means for all inflammation and infection, liver function, kidney function and blood tests over the four time points were not statistically significant. Given the absence of significant side effects associated with the utilization of UC-MSCs, it can be confidently concluded that these cells represent a promising therapeutic option for the effective management of MS. Their safety profile enhances their potential as a viable treatment alternative for patients. | ||
| کلیدواژه‌ها | ||
| Umbilical Cord Tissue؛ Mesenchymal Stem Cells؛ Multiple Sclerosis؛ Safety؛ Cell Therapy | ||
|
آمار تعداد مشاهده مقاله: 271 تعداد دریافت فایل اصل مقاله: 103 |
||